Covered recipient · General Payments record
DAREEN DARANEE SIRI
Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$234,819.98
320 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93,881.50 | 31 |
| Consulting Fee | $79,363.39 | 29 |
| Travel and Lodging | $26,984.44 | 69 |
| Honoraria | $24,066.00 | 9 |
| Food and Beverage | $10,468.22 | 178 |
| Education | $56.43 | 4 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $43,052.55 | 27 |
| Regeneron Healthcare Solutions, Inc. | $37,105.28 | 52 |
| ABBVIE INC. | $26,753.20 | 27 |
| Pharming Healthcare, Inc. | $24,117.11 | 31 |
| ADMA BioManufacturing LLC | $22,409.40 | 24 |
| Dermavant Sciences, Inc. | $19,938.81 | 19 |
| Incyte Corporation | $12,964.79 | 12 |
| Organon LLC | $9,707.65 | 8 |
| GlaxoSmithKline, LLC. | $7,842.57 | 21 |
| Hikma Pharmaceuticals USA | $7,787.87 | 4 |
| Genentech USA, Inc. | $7,428.82 | 9 |
| Blueprint Medicines Corporation | $4,021.85 | 5 |
| Consortium of Independent Immunology Clinics, LLC | $3,923.61 | 5 |
| Optinose US, Inc. | $3,402.32 | 8 |
| Arcutis Biotherapeutics, Inc. | $2,625.00 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $455.13 | 23 |
| AstraZeneca Pharmaceuticals LP | $251.63 | 4 |
| Novartis Pharmaceuticals Corporation | $238.00 | 4 |
| CSL Behring | $214.13 | 12 |
| Amgen Inc. | $186.36 | 6 |
| Grifols USA, LLC | $121.64 | 3 |
| PFIZER INC. | $110.86 | 9 |
| Octapharma USA, Inc. | $74.74 | 1 |
| BioCryst US Sales Co., LLC | $42.59 | 3 |
| LEO Pharma Inc. | $25.45 | 1 |
| Phathom Pharmaceuticals, Inc. | $18.62 | 1 |
Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAREEN DARANEE SIRI
NPI 1730272998 · CMS profile ID 33612
Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology
NORMAL, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1730272998?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAREEN DARANEE SIRI, NPI 1730272998, CMS profile ID 33612. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730272998?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). DAREEN DARANEE SIRI, NPI 1730272998, CMS profile ID 33612. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730272998?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- DAREEN DARANEE SIRI, NPI 1730272998, CMS profile ID 33612, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1730272998?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
320 matching records · $234,819.98 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 320.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Dermavant Sciences, Inc. | $317.39 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127935407 | CMS |
| Dermavant Sciences, Inc. | $197.00 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127935411 | CMS |
| Dermavant Sciences, Inc. | $69.14 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127935415 | CMS |
| Dermavant Sciences, Inc. | $32.00 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127935419 | CMS |
| Dermavant Sciences, Inc. | $658.42 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127935423 | CMS |
| Organon LLC | $6,360.00 | 10/24/2024 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239012453 | CMS |
| Organon LLC | $47.37 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239012455 | CMS |
| Organon LLC | $205.73 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239012457 | CMS |
| Organon LLC | $317.39 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239012459 | CMS |
| Organon LLC | $197.00 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239012461 | CMS |
| Organon LLC | $1,313.75 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239012463 | CMS |
| Organon LLC | $607.99 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239012465 | CMS |
| Organon LLC | $658.42 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239012467 | CMS |
| GENZYME CORPORATION | $2,447.00 | 10/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139741064 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $9.72 | 10/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137677493 | CMS |
| ADMA BioManufacturing LLC | $122.43 | 10/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149638950 | CMS |
| Pharming Healthcare, Inc. | $19.03 | 10/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132166021 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.68 | 10/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137677491 | CMS |
| Pharming Healthcare, Inc. | $1,800.00 | 10/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132166014 | CMS |
| ADMA BioManufacturing LLC | $85.37 | 10/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149638946 | CMS |
| ADMA BioManufacturing LLC | $31.46 | 10/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639242 | CMS |
| ADMA BioManufacturing LLC | $1,125.00 | 10/10/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639868 | CMS |
| ADMA BioManufacturing LLC | $150.00 | 10/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639898 | CMS |
| ADMA BioManufacturing LLC | $626.66 | 10/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639900 | CMS |
| ADMA BioManufacturing LLC | $286.83 | 10/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639902 | CMS |
| ADMA BioManufacturing LLC | $509.64 | 10/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639904 | CMS |
| ADMA BioManufacturing LLC | $332.31 | 10/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639906 | CMS |
| ADMA BioManufacturing LLC | $4,000.00 | 10/10/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639908 | CMS |
| GENZYME CORPORATION | $15.94 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139741046 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.23 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137677489 | CMS |
| GlaxoSmithKline, LLC. | $3.40 | 10/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116503259 | CMS |
| Octapharma USA, Inc. | $74.74 | 10/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142319397 | CMS |
| Pharming Healthcare, Inc. | $24.16 | 10/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132166005 | CMS |
| Regeneron Healthcare Solutions, Inc. | $133.62 | 09/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114177143 | CMS |
| Regeneron Healthcare Solutions, Inc. | $133.62 | 09/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114177148 | CMS |
| Regeneron Healthcare Solutions, Inc. | $0.95 | 09/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114177152 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2.85 | 09/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114177157 | CMS |
| Regeneron Healthcare Solutions, Inc. | $146.00 | 09/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114177162 | CMS |
| Regeneron Healthcare Solutions, Inc. | $22.92 | 09/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114177166 | CMS |
| GlaxoSmithKline, LLC. | $3,900.00 | 09/25/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116263023 | CMS |
| PFIZER INC. | $6.12 | 09/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131868338 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.91 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137677485 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.50 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137677487 | CMS |
| CSL Behring | $23.93 | 09/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134606135 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.85 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104612746 | CMS |
| Regeneron Healthcare Solutions, Inc. | $524.00 | 09/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114177139 | CMS |
| ABBVIE INC. | $3,300.00 | 09/13/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106114903 | CMS |
| ADMA BioManufacturing LLC | $210.50 | 09/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149640048 | CMS |
| ADMA BioManufacturing LLC | $707.43 | 09/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149640050 | CMS |
| ADMA BioManufacturing LLC | $2,500.00 | 09/13/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149640052 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $465,489.09 | 126 |
| PY2024 | Recipient | $4,750.00 | 1 |
| PY2024 | Principal investigator | $767,140.75 | 233 |
| PY2023 | Recipient | $22,816.68 | 41 |
| PY2023 | Principal investigator | $455,953.44 | 86 |
| PY2022 | Principal investigator | $409,335.19 | 101 |
| PY2021 | Principal investigator | $469,407.19 | 100 |
| PY2020 | Principal investigator | $805,855.03 | 139 |
| PY2019 | Principal investigator | $1,020,435.46 | 145 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
126 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 12/24/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184280226 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 12/19/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278562 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 12/19/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278564 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 12/19/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278566 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,894.20 | 12/08/2025 | Non-covered Recipient Entity Sneeze Wheeze Itch Associates | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226082831 |
| Principal investigator 1 | ABBVIE INC. | $2,423.80 | 12/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202527534 |
| Principal investigator 1 | Incyte Corporation | $1,459.00 | 12/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591720 |
| Principal investigator 1 | Incyte Corporation | $1,908.00 | 12/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591728 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 11/19/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184262449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,362.12 | 11/19/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184262453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 11/19/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184262455 |
| Principal investigator 1 | ABBVIE INC. | $1,807.19 | 11/05/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202522697 |
| Principal investigator 1 | Incyte Corporation | $1,479.60 | 11/05/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591731 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $928.80 | 10/23/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192188087 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,377.42 | 10/17/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 10/17/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251351 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,359.58 | 10/17/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,377.42 | 10/17/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251355 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,257.30 | 10/14/2025 | Non-covered Recipient Entity Sneeze Wheeze Itch Associates | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226082810 |
| Principal investigator 1 | ABBVIE INC. | $2,505.25 | 10/09/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202515077 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $377.50 | 10/02/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192098294 |
| Principal investigator 1 | Incyte Corporation | $1,585.80 | 10/02/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591724 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,356.78 | 10/01/2025 | Non-covered Recipient Entity MIDWEST ALLERGY SINUS ASTHMA, SC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190308410 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,326.00 | 09/22/2025 | Non-covered Recipient Entity Sneeze Wheeze Itch Associates | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226082794 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 09/15/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202510944 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 09/15/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184237468 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 09/15/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184237470 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 09/15/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184237472 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,323.88 | 09/15/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184237474 |
| Principal investigator 1 | ABBVIE INC. | $2,334.63 | 09/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202509756 |
| Principal investigator 1 | Incyte Corporation | $48.60 | 09/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591696 |
| Principal investigator 1 | Incyte Corporation | $1,644.00 | 09/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591701 |
| Principal investigator 1 | Incyte Corporation | $1,644.00 | 09/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591705 |
| Principal investigator 1 | Incyte Corporation | $3,590.00 | 09/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591709 |
| Principal investigator 1 | Incyte Corporation | $3,590.00 | 09/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591712 |
| Principal investigator 1 | Incyte Corporation | $3,590.00 | 09/04/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240591716 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 09/01/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223284667 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,271.30 | 08/25/2025 | Non-covered Recipient Entity Sneeze Wheeze Itch Associates | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226082789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,973.81 | 08/21/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184229505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,706.95 | 08/21/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184229507 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,413.12 | 08/21/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184229509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 08/21/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184229511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 08/21/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184229513 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,500.00 | 08/20/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON | No dispute reported | 06/30/2026 | 1185545571 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,350.00 | 08/20/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192098280 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,255.00 | 08/20/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192098287 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $975.00 | 08/20/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192189172 |
| Principal investigator 1 | ABBVIE INC. | $1,980.25 | 08/06/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202502370 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223283307 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,257.30 | 07/28/2025 | Non-covered Recipient Entity Sneeze Wheeze Itch Associates | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226082738 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,464.20 | 07/23/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192098307 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,307.40 | 07/22/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223282920 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,910.28 | 07/21/2025 | Non-covered Recipient Entity MIDWEST ALLERGY SINUS ASTHMA, SC | A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (LOU064) in adult and adolescent participants with IgE-mediated food allergy. | No dispute reported | 06/30/2026 | 1190311631 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,413.12 | 07/14/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184214896 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 07/14/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184214898 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $642.00 | 07/14/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184214900 |
| Principal investigator 1 | ABBVIE INC. | $3,669.91 | 07/02/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202494995 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $237.00 | 07/01/2025 | Non-covered Recipient Entity MIDWEST ALLERGY SINUS ASTHMA, SC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190311629 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 06/27/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211655 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 06/27/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211657 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 06/27/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211659 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,362.12 | 06/27/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211799 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,362.12 | 06/27/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211801 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,089.50 | 06/20/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192098300 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,270.50 | 06/19/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281622 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,773.00 | 06/16/2025 | Non-covered Recipient Entity Sneeze Wheeze Itch Associates | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226082691 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 06/14/2025 | Non-covered Recipient Entity Midwest Allergy Sinus Asthma SC | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228792194 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,970.80 | 06/12/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281092 |
| Principal investigator 1 | ABBVIE INC. | $7,902.58 | 06/03/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202488389 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,412.90 | 05/22/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223280126 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,516.40 | 05/21/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192189164 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,650.00 | 05/19/2025 | Non-covered Recipient Entity Sneeze Wheeze Itch Associates | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226082703 |
| Principal investigator 1 | UCB SA | $1,500.00 | 05/09/2025 | Non-covered Recipient Entity Sneeze, Wheeze And Itch Associates, Llc | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1246657196 |
| Principal investigator 1 | UCB SA | $14,000.00 | 05/09/2025 | Non-covered Recipient Entity Sneeze, Wheeze And Itch Associates, Llc | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1246657200 |
| Principal investigator 1 | UCB SA | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sneeze, Wheeze And Itch Associates, Llc | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1246657212 |
| Principal investigator 1 | UCB SA | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sneeze, Wheeze And Itch Associates, Llc | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1246657216 |
| Principal investigator 1 | UCB SA | $1,000.00 | 05/09/2025 | Non-covered Recipient Entity Sneeze, Wheeze And Itch Associates, Llc | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1246657247 |
| Principal investigator 1 | UCB SA | $1,500.00 | 05/09/2025 | Non-covered Recipient Entity Sneeze, Wheeze And Itch Associates, Llc | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1246657250 |
| Principal investigator 1 | UCB SA | $2,000.00 | 05/09/2025 | Non-covered Recipient Entity Sneeze, Wheeze And Itch Associates, Llc | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1246657253 |
| Principal investigator 1 | UCB SA | $7,000.00 | 05/09/2025 | Non-covered Recipient Entity Sneeze, Wheeze And Itch Associates, Llc | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1246657832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,359.58 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,706.95 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190477 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,323.88 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,973.81 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,323.88 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190487 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,359.58 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $642.00 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.20 | 04/28/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190493 |
| Principal investigator 1 | Amgen Inc. | $10,880.00 | 04/23/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) | No dispute reported | 06/30/2026 | 1246648290 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,840.10 | 04/23/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192189160 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,820.00 | 04/16/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192189168 |
| Principal investigator 1 | Eli Lilly and Company | $1,672.20 | 04/10/2025 | Non-covered Recipient Entity SNEEZE, WHEEZE & ITCH ASSOCIATES | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187888628 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,022.00 | 04/07/2025 | Non-covered Recipient Entity Sneeze Wheeze Itch Associates | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226082625 |
| Principal investigator 1 | ABBVIE INC. | $12,040.00 | 04/03/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202468907 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 04/01/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223277200 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,412.90 | 04/01/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223277250 |
| Principal investigator 1 | Incyte Corporation | $698.26 | 03/27/2025 | Non-covered Recipient Entity DIRECT HELPERS RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240528791 |
| Principal investigator 1 | PFIZER INC. | $1,666.60 | 03/22/2025 | Non-covered Recipient Entity Midwest Allergy Sinus Asthma SC | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228780837 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,055.72 | 03/20/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192188080 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,250.00 | 03/20/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192188091 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,800.60 | 03/11/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223276167 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,516.45 | 02/26/2025 | Non-covered Recipient Entity SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) | No dispute reported | 06/30/2026 | 1185545569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,706.95 | 02/26/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184155668 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $642.00 | 02/26/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184155670 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,973.81 | 02/26/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184155672 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $642.00 | 02/26/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184155674 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $642.00 | 02/26/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184155676 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,327.30 | 02/25/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192098313 |
| Principal investigator 1 | Incyte Corporation | $1,441.80 | 02/19/2025 | Non-covered Recipient Entity DIRECT HELPERS RESEARCH CENTER | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240528774 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,190.70 | 01/31/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185545573 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,527.86 | 01/30/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192188084 |
| Principal investigator 1 | Amgen Inc. | $64,847.75 | 01/29/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246648286 |
| Principal investigator 1 | Amgen Inc. | $44,678.26 | 01/27/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1246648282 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 01/27/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223274503 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,350.50 | 01/24/2025 | Non-covered Recipient Entity SNEEZE WHEEZE ITCH ASSOCIATES | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192098320 |
| Principal investigator 1 | Incyte Corporation | $5,575.15 | 01/23/2025 | Non-covered Recipient Entity DIRECT HELPERS RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240528786 |
| Principal investigator 1 | Incyte Corporation | $67.50 | 01/17/2025 | Non-covered Recipient Entity DIRECT HELPERS RESEARCH CENTER | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240528782 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $175.00 | 01/16/2025 | Non-covered Recipient Entity SNEEZE WHEEZE & ITCH ASSOCIATES | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223273945 |
| Principal investigator 1 | PFIZER INC. | $9,999.60 | 01/15/2025 | Non-covered Recipient Entity Midwest Allergy Sinus Asthma SC | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228798760 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,429.90 | 01/07/2025 | Non-covered Recipient Entity SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223273613 |
| Principal investigator 1 | Incyte Corporation | $168.00 | 01/02/2025 | Non-covered Recipient Entity DIRECT HELPERS RESEARCH CENTER | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240528770 |
| Principal investigator 1 | Incyte Corporation | $470.82 | 01/02/2025 | Non-covered Recipient Entity DIRECT HELPERS RESEARCH CENTER | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240528778 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,216.25 | 01/01/2025 | Non-covered Recipient Entity MIDWEST ALLERGY SINUS ASTHMA SC | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy | No dispute reported | 06/30/2026 | 1190306595 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $34,237.50 | 1 |
| PY2025 | Value of interest | $34,237.50 | 1 |
| PY2024 | Amount invested | $34,237.50 | 1 |
| PY2024 | Value of interest | $34,237.50 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
2 records · PY2024–2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | Consortium of Independent Immunology Clinics, LLC | $34,237.50 | $34,237.50 | n/a | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1228219705 |
| PY2024 | Consortium of Independent Immunology Clinics, LLC | $34,237.50 | $34,237.50 | n/a | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1147193724 |